Repligen ( (RGEN) ) has released its Q2 earnings. Here is a breakdown of the information Repligen presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Repligen Corporation is a global life sciences company specializing in bioprocessing technologies, serving biopharmaceutical drug developers and contract development and manufacturing organizations worldwide. In its second quarter of 2025, Repligen reported a revenue of $182 million, marking a 15% year-over-year increase, with a notable 17% organic growth excluding COVID-related revenue. Orders grew by over 20% year-over-year, reflecting strong demand across its portfolio. The company has raised its revenue guidance for the full year to a range of $715 to $735 million, indicating a 12.5% to 15.5% year-over-year non-COVID organic growth. Key highlights from the quarter include broad-based revenue strength across all franchises, with consumables and capital equipment showing significant growth. Repligen also launched a new product, the ProConnex® MixOne, and published its 2024 Sustainability report. Financially, the company achieved a GAAP net income of $15 million, up from $6 million the previous year, and an adjusted net income of $21 million. Looking ahead, Repligen remains optimistic about its growth prospects, despite facing headwinds from new modalities, and continues to focus on executing its strategic initiatives to drive further success.